Skip to content

US · TECH · BIOTECHNOLOGY

Bio-Techne Corporation (TECH) intrinsic value and stock valuation

$72.67as of 2026-11-21 · Mkt cap 11.27B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bio-Techne Corporation DCF and intrinsic value

InvestorsCraft values TECH with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from TECH’s statements →

Bio-Techne Corporation Graham Number

Graham Number: $11.30d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Minneapolis, MN 55413 bio-techne.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.22B+10.5% 5y CAGRd
20112025
Net income
$73.4M-20.4% 5y CAGRd
20112025
Free cash flow
$256.6M+10.8% 5y CAGRd
20112025
Total equity
$1.92B+6.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.22B$1.16B$1.14B$1.11B$931M
Operating income$102.3M$206.7M$298.9M$296.6M$237.3M
Net income$73.4M$168.1M$285.3M$272.1M$140.4M
EPSd$459.6K$1.05M$1.76M$1.66M$867.1K
Operating cash flow$287.6M$299M$254.4M$325.3M$352.2M
Capital expenditure-$-31.01M-$-62.88M-$-38.24M-$-44.91M-$-44.3M
Free cash flow$256.6M$236.1M$216.2M$280.4M$307.9M
Total assets$2.56B$2.7B$2.64B$2.29B$2.26B
Total debt$444.1M$419.5M$455M$326M$420.6M
Net debt$281.9M$267.8M$274.4M$153.4M$221.5M
Total equity$1.92B$2.07B$1.97B$1.7B$1.57B
Cash and short-term investments$162.2M$152.9M$204.3M$247M$231.6M
Income statement
20252024202320222021
Revenue$1.22B$1.16B$1.14B$1.11B$931M
Cost of revenue$429.4M$389.3M$366.9M$349.1M$298.2M
Gross profit$790.3M$769.7M$769.8M$756.5M$632.9M
Research and development expenses$99.5M$96.7M$92.5M$87.1M$70.6M
Selling, general and administrative expenses$415.1M$393.3M$352.4M$339M$289.9M
Other expenses$173.4M$73.1M$25.9M$33.8M$35M
Operating expenses$688M$563M$470.9M$459.9M$395.6M
Cost and expenses$1.12B$952.4M$837.8M$809M$693.7M
Interest income$3.89M$3.32M$3.41M$790K$470K
Interest expense$8.51M$15.7M$11.2M$11.3M$14M
Depreciation and amortization$109.9M$111.7M$107.2M$101.1M$87.8M
Ebitda$216.9M$313.1M$457.1M$413.8M$249.9M
Operating income$102.3M$206.7M$298.9M$296.6M$237.3M
Total other income/expenses, net-$-3.79M-$-21M$39.7M$4.8M-$-89.12M
Income before tax$98.5M$185.7M$338.7M$301.4M$148.2M
Income tax expense$25.1M$17.6M$53.2M$38.3M$8.59M
Net income$73.4M$168.1M$285.3M$272.1M$140.4M
Weighted average shares outstanding$157.5M$157.7M$157.2M$156.9M$155M
Weighted average diluted shares outstanding$159.7M$160.8M$161.9M$164.1M$161.9M
Balance sheet
20252024202320222021
Cash and short-term investments$162.2M$152.9M$204.3M$247M$231.6M
Net receivables$206.9M$241.4M$218.5M$194.6M$145.4M
Inventory$189.5M$179.7M$171.6M$141.1M$116.8M
Total current assets$608.3M$617.4M$621.5M$605.6M$510.6M
Property, plant and equipment, net$319.1M$342.4M$324.5M$288.8M$281.7M
Goodwill and intangible assets$1.35B$1.48B$1.41B$1.35B$1.46B
Long-term investments$251M$242.3M$255.9M$0.00$0.00
Total non-current assets$1.95B$2.09B$2.02B$1.69B$1.75B
Total assets$2.56B$2.7B$2.64B$2.29B$2.26B
Accounts payable$25.3M$38M$25.7M$33.9M$29.4M
Short-term debt$14.1M$12.9M$11.2M$24.4M$24.1M
Deferred revenue$32.6M$27.9M$23.1M$23.4M$19M
Total current liabilities$175.9M$159.4M$128.5M$176M$152.3M
Long-term debt$430M$406.6M$443.8M$301.5M$396.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$463.2M$475.6M$543.7M$417.8M$539.4M
Capital lease obligations$98.1M$100.5M$105M$70.1M$79.2M
Total liabilities$639.1M$635M$672.2M$593.8M$691.7M
Common stock$1.55M$1.58M$1.58M$1.57M$390K
Retained earnings$1.07B$1.33B$1.31B$1.12B$1.09B
Accumulated other comprehensive income (loss)-$-59.88M-$-78.32M-$-66.06M-$-75.2M-$-57.29M
Total equity$1.92B$2.07B$1.97B$1.7B$1.57B
Total investments$251M$243.4M$279.6M$74.5M$32.5M
Total debt$444.1M$419.5M$455M$326M$420.6M
Net debt$281.9M$267.8M$274.4M$153.4M$221.5M
Cash flow statement
20252024202320222021
Net income$73.4M$168.1M$285.4M$263.1M$139.6M
Depreciation and amortization$109.9M$111.7M$107.2M$101.1M$87.8M
Stock-based compensation$40.8M$38M$39.2M$42.2M$49M
Change in working capital$11.5M-$-10.11M-$-90.58M-$-69.52M$29.3M
Accounts receivable$42.6M-$-31.13M-$-23.36M-$-57.6M-$-15.55M
Inventory-$-18.14M-$-14.21M-$-30.17M-$-32.01M-$-7.14M
Accounts payable-$-13.95M$25.8M-$-7.91M$12.7M$19.1M
Net cash provided by operating activities$287.6M$299M$254.4M$325.3M$352.2M
Investments in property, plant and equipment-$-31.01M-$-62.88M-$-38.24M-$-44.91M-$-44.3M
Acquisitions, net-$-15M-$-169.71M-$-83.36M$0.00-$-225.91M
Net cash used for investing activities-$-35.18M-$-203.03M-$-265.65M-$-96.85M-$-243.52M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-275.73M-$-80.04M-$-19.56M-$-160.95M-$-43.18M
Dividends paid-$-50.39M-$-50.42M-$-50.28M-$-50.19M-$-49.62M
Net cash used for financing activities-$-253.91M-$-122.4M$22.6M-$-242.85M-$-62.55M
Net change in cash$10.4M-$-28.78M$8M-$-26.52M$52.5M
Cash at end of period$162.2M$151.8M$180.6M$172.6M$199.1M
Operating cash flow$287.6M$299M$254.4M$325.3M$352.2M
Capital expenditure-$-31.01M-$-62.88M-$-38.24M-$-44.91M-$-44.3M
Free cash flow$256.6M$236.1M$216.2M$280.4M$307.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bio-Techne Corporation

        Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

        CEO
        Kim Kelderman
        Employees
        3.1K
        Beta
        1.29

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Bio-Techne Corporation (TECH)?

        Bio-Techne Corporation (TECH) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TECH undervalued?

        TECH trades at a price of $72.67 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.